Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Naldi

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
NPJ Biofilms and Microbiomes|February 19, 2026
Exopolysaccharides of Lactobacillus crispatus mediate key balancing interactions with the vaginal mucosaVanessa Croatti, Caroline Dricot, Tom Eilers, et al.
Chembiochem : a European Journal of Chemical Biology|January 5, 2021
Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine MethyltransferaseVladimir O Talibov, Edoardo Fabini, Edward A FitzGerald, et al.
European Journal of Medicinal Chemistry|September 18, 2022
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3Marco Daniele Parenti, Marina Naldi, Elisabetta Manoni, et al.
RSC Medicinal Chemistry|August 6, 2021
Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid propertiesGiselle de Andrade Ramos, Andressa Souza de Oliveira, Manuela Bartolini, et al.
Journal of Medicinal Chemistry|March 10, 2022
Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's DiseaseSandra Codony, Caterina Pont, Christian Griñán-Ferré, et al.
British Journal of Pharmacology|January 26, 2026
Repurposing SGLT2 and DPP-4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular dockingShams T Osman, Perihan A Elzahhar, Md Abdul Hakim, et al.
European Journal of Medicinal Chemistry|August 21, 2021
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effectsCaterina Pont, Tiziana Ginex, Christian Griñán-Ferré, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 29, 2024
The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistancePaola Sanese, Katia De Marco, Martina Lepore Signorile, et al.
ACS Pharmacology & Translational Science|June 19, 2025
Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic DysfunctionPerihan A Elzahhar, Hisham A Nematalla, Malak A Abouayana, et al.
European Journal of Medicinal Chemistry|May 26, 2026
One destination, three routes: Tacrine-Celecoxib hybrids targeting cholinesterases, COX-2, and carbonic anhydrases in cognitive impairment linked to metabolic dysfunctionNayera W Hassan, Ola S Afifi, Maryam A Z El-Attar, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
NPJ Biofilms and Microbiomes|February 19, 2026
Exopolysaccharides of Lactobacillus crispatus mediate key balancing interactions with the vaginal mucosaVanessa Croatti, Caroline Dricot, Tom Eilers, et al.
Chembiochem : a European Journal of Chemical Biology|January 5, 2021
Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine MethyltransferaseVladimir O Talibov, Edoardo Fabini, Edward A FitzGerald, et al.
European Journal of Medicinal Chemistry|September 18, 2022
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3Marco Daniele Parenti, Marina Naldi, Elisabetta Manoni, et al.
RSC Medicinal Chemistry|August 6, 2021
Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid propertiesGiselle de Andrade Ramos, Andressa Souza de Oliveira, Manuela Bartolini, et al.
Journal of Medicinal Chemistry|March 10, 2022
Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's DiseaseSandra Codony, Caterina Pont, Christian Griñán-Ferré, et al.
British Journal of Pharmacology|January 26, 2026
Repurposing SGLT2 and DPP-4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular dockingShams T Osman, Perihan A Elzahhar, Md Abdul Hakim, et al.
European Journal of Medicinal Chemistry|August 21, 2021
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effectsCaterina Pont, Tiziana Ginex, Christian Griñán-Ferré, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 29, 2024
The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistancePaola Sanese, Katia De Marco, Martina Lepore Signorile, et al.
ACS Pharmacology & Translational Science|June 19, 2025
Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic DysfunctionPerihan A Elzahhar, Hisham A Nematalla, Malak A Abouayana, et al.
European Journal of Medicinal Chemistry|May 26, 2026
One destination, three routes: Tacrine-Celecoxib hybrids targeting cholinesterases, COX-2, and carbonic anhydrases in cognitive impairment linked to metabolic dysfunctionNayera W Hassan, Ola S Afifi, Maryam A Z El-Attar, et al.
Pageof 7